Showcases Stock ranks Forex

Viatris Inc (VTRS)
10.09  0.36 (3.7%) 08-08 16:00
Open: 10.18 Pre. Close: 9.73
High: 10.62 Low: 10.02
Volume: 42,499,418 Market Cap: 12,232M
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 10.633 - 10.673 10.673 - 10.704
Low: 9.917 - 9.965 9.965 - 10.004
Close: 10.018 - 10.092 10.092 - 10.151
Stock Technical Analysis
Target: Six months: 12.40
One year: 14.49
Support: Support1: 9.90
Support2: 9.45
Resistance: Resistance1: 10.62
Resistance2: 12.40
Pivot: 9.82
Moving Averages: MA(5): 9.78
MA(20): 9.85
MA(100): 10.71
MA(250): 12.44
MACD: MACD(12,26): -0.18
Signal(12,26,9): -0.23
%K %D: %K(14,3): 37.46
%D(3): 33.57
RSI: RSI(14): 51.52
52-Week: High: 15.6
Low: 9.45
Change(%): -32.3
Average Vol(K): 3-Month: 11314
10-Days: 14784
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ VTRS ] has closed below upper band by 9.1%. Bollinger Bands are 48.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
Viatris (VTRS) Surpasses Q2 Earnings Estimates - Benzinga

Mon, 08 Aug 2022
Viatris Inc. (VTRS) CEO Michael Goettler on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Mon, 08 Aug 2022
Viatris Inc Tops Q2 EPS by 5c By - India

Mon, 08 Aug 2022
Viatris declares $0.12 dividend (NASDAQ:VTRS) - Seeking Alpha

Mon, 08 Aug 2022
Viatris: Q2 Earnings Snapshot - Greenwich Time

Mon, 08 Aug 2022
Today's Stock Market News & Events: 8/8/2022 - Schaeffers Research

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. (M) 1210.00
Shares Float (M) 1210.00
% Held by Insiders 0.21
% Held by Institutions 75.25
Shares Short (K) 27470
Shares Short Prior Month (K) 24040
Stock Financials
EPS 0.140
Book Value (p.s.) 16.870
Profit Margin 0.95
Operating Margin 17.63
Return on Assets (ttm) 3.5
Return on Equity (ttm) 0.8
Qtrly Rev. Growth -5.4
Gross Profit (p.s.) 6.405
Sales Per Share 14.587
EBITDA (p.s.) 4.661
Qtrly Earnings Growth
Operating Cash Flow (M) 3310.00
Levered Free Cash Flow (M) 2890.00
Stock Valuation
PE Ratio 72.07
PEG Ratio -2.14
Price to Book value 0.60
Price to Sales 0.69
Price to Cash Flow 3.69
Stock Dividends
Dividend 0.120
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android